LOGIN  |  REGISTER
Terns Pharmaceuticals

Integer to Present at Raymond James & Associates’ 46th Annual Institutional Investor Conference and KeyBanc Capital Markets Healthcare Forum

February 18, 2025 | Last Trade: US$119.77 2.00 -1.64

PLANO, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced participation at the following upcoming investor conferences.

  • Integer will participate at the 2025 Raymond James & Associates’ 46th Annual Institutional Investor Conference, to be held March 3-5, 2025, in Orlando, Florida. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present on Wednesday, March 5, 2025, at 11:00 a.m. ET.
  • Integer will participate at the 2025 KeyBanc Capital Markets Healthcare Forum, to be held virtually March 18-19, 2025. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to participate in a virtual fireside chat on Wednesday, March 19, 2025, at 9:45 a.m. ET.

A live webcast of each presentation will be accessible under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net.

Learn more about Integer at www.integer.net.

About Integer®

Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.

Investor Relations:
Andrew Senn
This email address is being protected from spambots. You need JavaScript enabled to view it.
763.951.8312 
Media Relations:
Kelly Butler
This email address is being protected from spambots. You need JavaScript enabled to view it.
469.731.6617
Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page